19 May 2013
Keywords: strong, early, ph, data, amira, am103, usa
Article | 23 July 2007
The USA's Amira Pharmaceuticals, a small-molecule drugmaker focused on inflammatory diseases linked to the eicosanoid pathway, has reported
positive initial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 July 2007
17 May 2013
© 2013 thepharmaletter.com